17-AAG is an HSP90 inhibitor that promotes degradation of mutant p53 [45] with reported efficacy in primary leukemia cells from patients with MM, AML and chronic lymphocytic leukemia (CLL) [46]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.